Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CAPS Capstone Therapeutics	$1.24 -3.9%	$1.60	$1.20 ▼ $16.18	$198K	-0.8	413,399 shs	410,890 shs
PBLA Panbela Therapeutics	$0.16	$0.20	$0.05 ▼ $0.47	$767K	1.33	16,553 shs	160 shs
SRNE Sorrento Therapeutics	$0.00 -67.2%	$0.00	$0.00 ▼ $0.02	$1.16M	0.85	116,158 shs	1.26 million shs
ZVSA ZyVersa Therapeutics	$0.15 +2.4%	$0.45	$0.12 ▼ $3.96	$1.23M	0.75	3.46 million shs	147,854 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CAPS Capstone Therapeutics	+3.20%	-2.27%	-14.57%	-47.35%	+128,999,900.00%
PBLA Panbela Therapeutics	0.00%	0.00%	-34.04%	-36.84%	-54.89%
SRNE Sorrento Therapeutics	+220.00%	+326.67%	+357.14%	+481.82%	-20.00%
ZVSA ZyVersa Therapeutics	+0.40%	-11.35%	-72.53%	-71.16%	-94.31%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CAPS Capstone Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PBLA Panbela Therapeutics	1.1218 of 5 stars	0.0	5.0	0.0	0.0	3.9	0.0	0.0
SRNE Sorrento Therapeutics	0.8432 of 5 stars	0.0	2.0	0.0	4.3	0.6	0.0	0.0
ZVSA ZyVersa Therapeutics	0.7377 of 5 stars	0.0	4.0	0.0	0.0	2.3	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
CAPS Capstone Therapeutics	N/A	N/A	N/A
PBLA Panbela Therapeutics	N/A	N/A	N/A
SRNE Sorrento Therapeutics	N/A	N/A	N/A
ZVSA ZyVersa Therapeutics	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CAPS Capstone Therapeutics	$44.88M	0.00	N/A	N/A	($19.40) per share	-0.06
PBLA Panbela Therapeutics	N/A	N/A	N/A	N/A	($18.37) per share	N/A
SRNE Sorrento Therapeutics	$60.32M	0.02	N/A	N/A	N/A	∞
ZVSA ZyVersa Therapeutics	N/A	N/A	N/A	N/A	$3.40 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CAPS Capstone Therapeutics	-$2.56M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
PBLA Panbela Therapeutics	-$25.26M	-$71.13	N/A	∞	N/A	N/A	N/A	-302.61%	N/A
SRNE Sorrento Therapeutics	-$572.84M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ZVSA ZyVersa Therapeutics	-$9.41M	N/A	0.00	N/A	N/A	N/A	-109.54%	-43.95%	N/A

Latest CAPS, ZVSA, SRNE, and PBLA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/15/2025	Q2 2025	CAPS Capstone Therapeutics	N/A	-$0.13	N/A	-$0.13	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CAPS Capstone Therapeutics	N/A	N/A	N/A	N/A	N/A
PBLA Panbela Therapeutics	N/A	N/A	N/A	N/A	N/A
SRNE Sorrento Therapeutics	N/A	N/A	N/A	N/A	N/A
ZVSA ZyVersa Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CAPS Capstone Therapeutics	0.28	1.14	0.47
PBLA Panbela Therapeutics	N/A	0.26	0.26
SRNE Sorrento Therapeutics	N/A	N/A	N/A
ZVSA ZyVersa Therapeutics	N/A	0.18	0.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CAPS Capstone Therapeutics	2.55%
PBLA Panbela Therapeutics	4.37%
SRNE Sorrento Therapeutics	0.02%
ZVSA ZyVersa Therapeutics	3.91%

Insider Ownership

Company	Insider Ownership
CAPS Capstone Therapeutics	42.80%
PBLA Panbela Therapeutics	0.01%
SRNE Sorrento Therapeutics	2.60%
ZVSA ZyVersa Therapeutics	0.21%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CAPS Capstone Therapeutics	38	160,000	90,000	N/A
PBLA Panbela Therapeutics	6	4.86 million	4.86 million	Not Optionable
SRNE Sorrento Therapeutics	800	551.28 million	536.95 million	No Data
ZVSA ZyVersa Therapeutics	2	7.94 million	4.86 million	Not Optionable

CAPS, ZVSA, SRNE, and PBLA Headlines

Recent News About These Companies

ZyVersa Therapeutics reports Q2 EPS (46c) vs. ($3.31) last year

August 14 at 7:07 PM | msn.com

ZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address ...

August 14 at 7:07 PM | bakersfield.comB

ZyVersa Therapeutics highlights data on role of lipotoxicity in DKD

August 14 at 7:07 PM | msn.com

ZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address Kidney Lipotoxicity to Alleviate Diabetic Kidney Disease (DKD) and Its Progression

August 14 at 8:04 AM | globenewswire.com

ZyVersa Therapeutics Activates First Clinical Site for Phase 2a Trial of VAR 200 in Diabetic Kidney Disease and Reports Progress in Product Development

August 13 at 9:29 AM | quiverquant.comQ

ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones

August 13 at 9:00 AM | globenewswire.com

ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D Progress

July 21, 2025 | globenewswire.com

ZyVersa Touches 52-Week Low; Nasdaq to Suspend Trading Thursday

July 16, 2025 | marketwatch.com

ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds | Morningstar

July 9, 2025 | morningstar.comM

ZyVersa’s VAR 200 approved for emergency use in rare kidney disease

July 9, 2025 | uk.investing.com

ZyVersa Therapeutics Supports Emergency Compassionate Use of VAR 200 for Patient with ApoCII Amyloidosis - Nasdaq

July 9, 2025 | nasdaq.com

Why Did ZyVersa Therapeutics Stock Shoot Higher On Tuesday?

July 8, 2025 | benzinga.com

ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds

July 8, 2025 | globenewswire.com

ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator VAR 200 in a Patient with ApoCII Amyloidosis

July 8, 2025 | finanznachrichten.de

ZyVersa Therapeutics Supports Emergency Compassionate Use of VAR 200 for Patient with ApoCII Amyloidosis

July 8, 2025 | quiverquant.comQ

ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediatorâ„¢Â VAR 200 in a Patient with ApoCII Amyloidosis

July 8, 2025 | globenewswire.com

ZyVersa Therapeutics Enters Share Purchase Agreement with Williamsburg Venture Holdings to Advance Clinical Development of VAR 200 - Nasdaq

June 27, 2025 | nasdaq.com

ZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million in Partnership with Williamsburg Venture Holdings to Fund Clinical Development of Cholesterol ...

June 26, 2025 | morningstar.comM

ZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator™ VAR 200’s Phase 2a Clinical Trial in Patients ...

June 26, 2025 | finance.yahoo.com

ZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediatorâ„¢ VAR 200's Phase 2a Clinical Trial in Patients with Diabetic Kidney Disease (DKD)

June 26, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CAPS, ZVSA, SRNE, and PBLA Company Descriptions

Capstone Therapeutics NASDAQ:CAPS

$1.24 -0.05 (-3.88%)

As of 04:00 PM Eastern

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.

Panbela Therapeutics NASDAQ:PBLA

$0.16 0.00 (0.00%)

As of 10:50 AM Eastern

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

Sorrento Therapeutics NASDAQ:SRNE

$0.0021 0.00 (-67.19%)

As of 03:50 PM Eastern

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.

ZyVersa Therapeutics NASDAQ:ZVSA

$0.15 +0.00 (+2.39%)

As of 03:41 PM Eastern

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time